Differential isoform profiles of alpha 2-macroglobulin from plasma of patients with chronic-progressive or relapsing-remitting multiple sclerosis.
Differential isoform profiles of alpha 2-macroglobulin from plasma of patients with chronic-progressive or relapsing-remitting multiple sclerosis.
复制标题
慢性进行性或复发缓解型多发性硬化症患者血浆中 α2-巨球蛋白的差异亚型谱。
DOI：
10.1016/0009-8981(92)90102-v
复制
发表时间：
1992
期刊：
影响因子：
--
通讯作者：
Alhadeff,JA
中科院分区：
文献类型：
--
作者：
Back,SA;Alhadeff,JA
多发性硬化症(MS)是一种人类神经系统疾病，在血液中还没有发现临床上有用的标志物。本研究检测了6例慢性进展型多发性硬化症患者和6例复发缓解型多发性硬化症患者血浆中的α-2-巨球蛋白(α-2M)。两组患者血浆中α-2M胰酶结合活性与正常对照组无明显差异。然而，柱等电聚焦后，从MS样本中恢复的α2M活性一直较低：慢性进展组和复发缓解组的平均活性分别为对照组的43%和68%。慢性进展性疾病患者α2M亚型的数目和等电点(PI)值与对照组相似。两组的平均PIOF(主要形式)为6.6。相比之下，复发-缓解期MS患者的平均PIOF(主要形式)显著升高至7.1，并且这组患者的总恢复活动的百分比显著高于pH 7.0。在接受检查的12例患者中，有11例的PIOF(α2M的主要形式)与患者的临床状态正确相关。通过9年的回顾性访谈，对患者的原始临床诊断进行重新评估，证实在随访组的10例患者中，有9例保留了原始的临床诊断。这些研究表明，进展期和缓解期MS患者的天然α2m亚型不同，这可能有助于MS患者的亚型划分。
Multiple sclerosis (MS) is a human neurological disease for which no clinically useful marker has been identified in blood. This study examinedα2-macroglobulin (α2M) from the plasma of six patients with chronic-progressive MS and six with relapsing-remitting disease. Theα2M trypsin-binding activity in the plasma from both groups of patients did not differ from normal controls. However, after column isoelectric focusing, consistently lessα2M activity was recovered from the MS samples: those from the chronic-progressive and relapsing-remitting disease groups were an average of 43% and 68%, respectively, of controls. The number and isoelectric point (pI) values of the isoforms of theα2M from patients with chronicprogressive disease were similar to controls. The average pIof the major form for both groups was 6.6. By contrast, the average pIof the major form from the patients with relapsing-remitting MS was significantly elevated to 7.1, and this group displayed a significantly higher percentage of total recovered activity above pH 7.0. In eleven of the twelve cases examined, the pIof the major form ofα2M correctly correlated with the clinical status of the patient. The original clinical diagnosis of the patients was reassessed by a 9-year retrospective interview which verified that 9 of the 10 patients in the follow-up group retained their original clinical diagnosis. These studies demonstrate differential isoform profiles of nativeα2M from MS patients with progressive versus remitting disease which may be useful in subclassifying MS patients.